Skip to content

BCBS Arkansas

Does BCBS Arkansas cover Wegovy for Liver Disease (MASH)?

Yes. BCBS Arkansas covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with F2-F3 Fibrosis - Adult

All of:

  • Patient is an adult (18 years or older)
  • Request is NOT for Wegovy HD 7.2 mg injection OR Wegovy tablets
  • Used with a reduced-calorie diet AND increased physical activity
  • Diagnosis of noncirrhotic MASH (formerly NASH) with moderate to advanced liver fibrosis (stages F2 to F3)
  • Prescribed by or in consultation with a gastroenterologist or hepatologist
  • Moderate to advanced liver fibrosis (F2-F3) confirmed at baseline by non-invasive liver disease assessment (e.g., ultrasound-based elastography or MRE) OR historical liver biopsy

Documentation to bring

  • Documentation of baseline moderate to advanced liver fibrosis (F2-F3) confirmed by non-invasive liver disease assessment (ultrasound-based elastography or MRE) OR historical liver biopsy
  • Prescriber attestation of gastroenterologist or hepatologist involvement (prescribing or consulting)
  • Documentation of positive clinical response (e.g., reduction in ALT, improvement in ELF score, improvement in liver stiffness by elastography or MRE) (for continuation)

Quantity limits

  • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL — 2 mL (1 package of 4 pens) / 21 days; 6 mL (3 packages of 4 pens each) / 63 days (84-day)
  • 1.7mg/0.75mL, 2.4mg/0.75mL — 3 mL (1 package of 4 pens) / 21 days; 9 mL (3 packages of 4 pens each) / 63 days (84-day)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must have achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, improvement in ELF score, improvement in liver stiffness measurement by ultrasound-based elastography or MRE). Patient must be on a maintenance dose based on individual treatment response and tolerability. Documentation required. Note: initial fibrosis confirmation (F2-F3) and specialist requirement are not explicitly re-verified at continuation.

Not covered when

  • Wegovy HD 7.2 mg injection is explicitly excluded for the MASH indication
  • Wegovy tablets are explicitly excluded for the MASH indication
  • Cirrhotic patients are excluded (noncirrhotic MASH only)
  • Concomitant use with other semaglutide-containing products is not recommended
  • Concomitant use with any other GLP-1 receptor agonist is not recommended

Policy note: MASH indication is restricted to Wegovy injection (standard strengths only); Wegovy HD 7.2 mg injection and Wegovy tablets are explicitly excluded. No specific lookback periods are stated for fibrosis confirmation; historical biopsy is acceptable. Fibrosis confirmation methods include ultrasound-based elastography (FibroScan VCTE), MRE, or historical liver biopsy. The policy notes this indication was approved under accelerated approval and continued approval may be contingent on confirmatory trial results. DOA is 12 months for both initial and continuation.

verified June 2, 2026 · source: 4774 C Wegovy · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Arkansas cover Wegovy?
Yes. BCBS Arkansas covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with BCBS Arkansas?
Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Arkansas require to renew Wegovy?
Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Patient must have achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, improvement in ELF score, improvement in liver stiffness measurement by ultrasound-based elastography or MRE). Patient must be on a maintenance dose based on individual treatment response and tolerability. Documentation required. Note: initial fibrosis confirmation (F2-F3) and specialist requirement are not explicitly re-verified at continuation.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Arkansas: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: BCBS Alabama, BCBS Arizona, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, BCBS North Carolina

All insurance plans · All medications

Summary of BCBS Arkansas's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.